NST-628 is a Brain-Penetrant RAS-MAPK Pathway Inhibitor for RAS/RAF-Driven Cancers Research.
The dysregulation of the RAS-MAPK (RAS-RAF-MEK-ERK) pathway is a common occurrence in tumor development, representing a crucial clinical target in precision oncology. Specific inhibitors have shown varied success rates in…